HRQOL the Same With CDK4/6 Inhibitors in 1st or 2nd Line

An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 inhibitors were similar regardless of treatment timing.
Medscape Medical News

source https://www.medscape.com/viewarticle/hrqol-same-cdk4-6-inhibitors-1st-or-2nd-line-breast-cancer-2024a1000oq4?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?